A Systematic Patient‐Derived Xenograft Based Solution for Preclinical Biomarker Discovery

Tumor heterogeneity is a major hurdle for cancer treatment success. To effectively enroll patients in clinical trials, the identification of predictive biomarkers at the preclinical stage is crucial. The use of patient-derived xenograft (PDX) tumor models facilitates the identification of biomarkers that predict the tumor’s response to therapy. In addition, the assessment of PDX models on broad screening platforms such as 3D culture and in vivo mouse clinical trials (humanized and immunodeficient) accelerates compound evaluation.

Nach Vereinbarung: Ja
Referent: Herr Ph.D. Vincent Vuaroqueaux
Sprache: Englisch
Mehr über Charles River
  • Veranstaltungen

    The Operational Impact of Celsis ® Rapid Micro Methods

    As the world’s leading innovator in rapid microbial detection, Celsis ® systems are used globally by leading manufacturers in the Pharmaceutical, Home & Beauty and Dairy, Beverage & Food industries. Learn how the Celsis ® systems deliver quality assurance results in as few as 24 hours, enab ... mehr


    Nuclear Imaging of CNS Diseases in Rodent Models

    Nuclear imaging provides translational and noninvasive in vivo methodology to reliably quantify pathological changes during disease progression and allows evaluation of therapeutic effects of existing or novel drugs against the disease. This webinar showcases new developments of CNS Discove ... mehr


    High-Throughput Screening: An Insider’s Guide to Outsourcing

    High-throughput screening (HTS) is an established means to identify starting points in the drug discovery process. As a significant investment is necessary to undertake high-throughput screening efficiently, screening is increasingly being outsourced by researchers in the not-for-profit, bi ... mehr

  • News

    Protagen und Charles River bilden strategische Partnerschaft

    Die Protagen AG und Charles River Laboratories International Inc. sind eine strategische Partnerschaft eingegangen, um gemeinsam analytische Dienstleistungen von der Zelllinienentwicklung bis hin zur Batchfreigabe von Biopharmazeutika anbieten zu können. Im Rahmen des zunächst auf zwei Jahr ... mehr

    Charles River Acquires NewLab BioQuality AG

    Charles River announced the acquisition of privately-held NewLab BioQuality AG (NewLab), a Dusseldorf, Germany-based contract service organization that provides safety and quality control services to biopharmaceutical clients. NewLab has approximately 150 employees. Both Charles River and ... mehr

Ihr Bowser ist nicht aktuell. Microsoft Internet Explorer 6.0 unterstützt einige Funktionen auf Chemie.DE nicht.